Navigation Links
Significant funding for type 1 diabetes research
Date:1/25/2008

Researchers from the Peninsula Medical School in the South West of England have received funding of $480,000 from the Juvenile Diabetes Research Foundation, the worlds largest charitable funder of type 1 diabetes research, to study a unique collection of pathology samples from people who died soon after diagnosis of Type 1 diabetes.

The aim of the research, which will use around 70 samples collected by Dr Alan Foulis, a pathologist from Glasgow, is to identify the triggers that cause Type 1 diabetes and the sequence of events that lead to the first symptoms.

Type 1 diabetes develops when the body is unable to produce its own insulin. Type 1 diabetes is an autoimmune disease which strikes in childhood, adolescence, or adulthood, but lasts a lifetime. It accounts for between five per cent and 15 per cent of all people with diabetes. It also requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.

The research will cover new ground by seeking to identify what it is that initiates the process in man, and will consider the possibility that Type 1 diabetes could be triggered by environmental factors such as certain viruses. It will also map the progression of the disease in relation to the immune system and will seek to establish if there is a defined sequence of events, and why this is so.

Professor Noel Morgan from the Peninsula Medical School commented: This is very exciting research which can be expected to provide new insights into the causes of diabetes. If we can identify the triggers that set Type 1 diabetes into motion, and the sequence of events that lead to symptoms, there is potential for the development of therapies to prevent or halt the disease.

He added: The process can start as long as five years before the first symptoms appear. If we can understand what it is that goes on in this period, it could provide a window of opportunity for us to develop therapies and treatments to stop it.

The funding from the Juvenile Diabetes Research Foundation will be used to support a post-doctorate researcher and a graduate student researcher for three years. The research will be based at the Peninsula Medical School but the team also includes collaborators from Glasgow and the School of Pharmacy & Biomolecular Sciences, University of Brighton.

Said Professor Morgan: We are very grateful to the Juvenile Diabetes Research Foundation for this grant. The outcomes of our research could well have a fundamental effect on the prevention and treatment of Type 1 diabetes in the future.

Diabetes affects 2.3 million people in the UK, and 20.8 million in the USA. In the UK, a further 750,000 people may have the disease without knowing it in the USA this figure is 6.2 million.


'/>"/>

Contact: Andrew Gould
media@pr-works.co.uk
01-392-686-107
The Peninsula College of Medicine and Dentistry
Source:Eurekalert

Related medicine news :

1. Study finds significant differences in protocols hospitals use to determine brain death
2. Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers
3. Despite efforts, significant racial disparities in cancer therapy still exist
4. Tonsillectomy significantly improves quality of life in adult and pediatric patients
5. Significant changes in plastic surgery expected in 2008
6. Adult ADHD significantly impacts on social, financial and personal aspects of life
7. Recent studies confirm significant underuse of colorectal cancer screening
8. VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
9. Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
10. A Major Gift of Art and History: U-M Receives 45 Significant Medical Paintings From Pfizer
11. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
(Date:6/28/2017)... Church, VA (PRWEB) , ... June 28, 2017 , ... ... http://www.fdanews.com/fdaeumdregs      , No matter on which side of the Atlantic devicemakers ... medical device regulations they have to follow. , In addition to the full text ...
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest mortality ... at least one person dies as a direct result from an eating disorder in ... qualified treatment providers. The iaedp Foundation meets this challenge by offering what has become ...
(Date:6/28/2017)... ... June 28, 2017 , ... American Farmer proudly announces the participation of ... winning television series, scheduled to broadcast fourth quarter 2017. American Farmer airs Tuesdays at ... supplier of garden pea seed. As demand grew, the small company located in Moscow, ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... insurance management and financial planning assistance to clients in southern Montana, is announcing ... offered by Zoo Montana. , The outreach programs offered by Zoo Montana provide ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... of two Phase 2 trials of its RSV F protein ... child bearing age have been published in the journal ... have been shared in prior scientific conferences). The Company previously ... April 2014. Novavax is developing the RSV F Vaccine with ...
(Date:6/2/2017)... Mass. , June 2, 2017  NxStage Medical, ... renal care, today announced new findings demonstrating positive biochemical ... ® System One™. The data will be presented ... in Madrid, Spain . ... to Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology: